Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Bioscience Corp. on November 13, 2019, with the report date of November 13, 2019. The filing discloses a completed non-brokered private placement offering.
Key Financial Metrics
- Capital Raised: US$699,410.25
- Securities Issued: 1,554,245 Units
- Offering Price: US$0.45 per Unit
- Transaction Costs: US$3,937.50 paid to finders
- Additional Warrants Issued: 8,750 Warrants issued to finders
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in equity capital and the expansion of the share count due to the issuance of 1,554,245 Units. Each Unit consists of one common share and one share purchase warrant.
Offering Terms and Structure
- Warrant Terms: Each Warrant allows the purchase of one additional share.
- Exercise Price: US$0.80 per share until November 13, 2020, and US$1.20 per share thereafter.
- Expiration: The filing text contains a contradiction regarding the expiration date, stating "until November 13, 2020" for both the initial and subsequent exercise periods. The filing text does not provide a clear final expiration date beyond the price adjustment date.
- Investor Eligibility: Sold to investors who are neither officers nor directors, relying on exemptions for accredited investors or non-US persons in offshore transactions.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance.
- Confirm the specific expiration date of the warrants, as the filing text appears to contain a typographical error regarding the term.
- Review the use of proceeds for the US$699,410.25 raised.
- Check for any subsequent filings regarding the registration status of these securities in the United States.